Core Viewpoint - Telix Pharmaceuticals Limited is under investigation for potential claims related to a federal securities class action, with a deadline for investors to seek lead plaintiff status set for January 9, 2026 [1] Group 1 - Faruqi & Faruqi, LLP, a prominent national securities law firm, is leading the investigation into Telix Pharmaceuticals [1] - The investigation pertains to potential claims against Telix Pharmaceuticals Limited, which trades on NASDAQ under the ticker TLX [1]

Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and regulatory compliance, which resulted in significant investor losses [1][2][3]. Regulatory Issues - The lawsuit follows regulatory setbacks, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, leading to a 21% decline in stock price [2][6]. - The SEC is questioning the development disclosures, while the FDA rejected a Biologics License Application (BLA) due to deficiencies in Chemistry, Manufacturing, and Controls (CMC) at third-party manufacturers [3][6]. Allegations of Misrepresentation - The complaint alleges that Telix and its executives overstated the developmental progress of therapeutic candidates and misrepresented the reliability of their supply chain and manufacturing partners [2][3]. - Documented failures in regulatory compliance were allegedly concealed, contradicting claims of "great progress" and "global manufacturing capability" [3][4]. Investor Impact - Investors who purchased Telix ADSs during the Class Period (February 21, 2025 – August 28, 2025) reportedly suffered substantial losses due to undisclosed flaws in supply chain and therapeutic progress [5][6]. - The cumulative effect of the regulatory disclosures led to a sharp decline in Telix ADSs, with a notable 21% drop following the final regulatory news [6]. Next Steps for Investors - Hagens Berman encourages affected Telix investors to contact the firm to discuss their rights and potential recovery options [4][5].

Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On December 30, TD Cowen lowered its price target on Telix Pharmaceuticals Limited (NASDAQ:TLX) from AUD 35 to AUD 25 but kept its Buy rating on the stock. Earlier, on December 14, RBC Capital also initiated coverage on Telix Pharmaceuticals Limited (NASDAQ:TLX), assigning the stock a Sector Perform rating and setting the price target at AUD 17. The firm noted that Telix Pharmaceutic ...

Core Viewpoint - Rosen Law Firm is reminding purchasers of Telix Pharmaceuticals Ltd. securities about the upcoming lead plaintiff deadline for a securities class action lawsuit, indicating potential compensation for eligible investors [1] Summary by Relevant Sections - **Company Information** - Telix Pharmaceuticals Ltd. is involved in a securities class action lawsuit for transactions that occurred between February 21, 2025, and August 28, 2025 [1] - **Legal Action Details** - The lead plaintiff deadline for the class action is set for January 9, 2026, highlighting the importance of timely action for affected investors [1] - **Investor Implications** - Investors who purchased Telix securities during the specified class period may be entitled to compensation without any out-of-pocket expenses [1]

Core Viewpoint - The Gross Law Firm is notifying shareholders of Telix Pharmaceuticals Ltd. regarding a class action lawsuit due to alleged misleading statements made by the company during a specified class period [1][3]. Group 1: Allegations - The complaint alleges that during the class period from February 21, 2025, to August 28, 2025, Telix Pharmaceuticals materially overstated its progress with prostate cancer therapeutic candidates [3]. - It is claimed that the company also overstated the quality of its supply chain and partners, leading to false and misleading statements about its business operations and prospects [3]. Group 2: Class Action Details - Shareholders who purchased shares of TLX during the class period are encouraged to register for the class action, with a deadline set for January 9, 2026 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be ...

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/telix-pharmaceuticals-ltd-loss-submission-form/?id=182840&from=4  CLASS PERIO ...

MELBOURNE, Australia and INDIANAPOLIS, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.). Telix will host a presentation on Monday, 12 January at 9:00 am PST (12:00 pm EST / 4:00 am AEDT, 13 January), providing an overview of the Company’s pipeline assets alongside its comm ...

MELBOURNE, Australia and INDIANAPOLIS, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.).  Telix will host a presentation on Monday, 12 January at 9:00 am PST (12:00 pm EST / 4:00 am AEDT, 13 January), providing an overview of the Company’s pipeline assets alongside its comm ...

Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and supply chain reliability, leading to significant investor losses [1][2][3]. Regulatory Issues - The lawsuit follows regulatory setbacks, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in Telix's stock [2][8]. - The SEC is investigating Telix's disclosures related to the development of its prostate cancer therapeutic candidates, suggesting misleading statements about their advancement [8]. Allegations of Misrepresentation - The complaint alleges that Telix and its executives overstated the developmental progress of its therapeutic candidates and misrepresented the reliability of its third-party supply chain and manufacturing partners [2][3]. - Specific failures cited include deficiencies in Chemistry, Manufacturing, and Controls (CMC) and Form 483 notices issued to third-party manufacturers, which were allegedly concealed from investors [3][8]. Investor Impact - The cumulative effect of the regulatory disclosures reportedly caused significant financial damage to investors who purchased Telix ADSs during the Class Period from February 21, 2025, to August 28, 2025 [8]. - The firm representing the investors, Hagens Berman, is actively advising those who suffered losses due to undisclosed flaws in the supply chain and therapeutic progress [5][4].